The proteomic landscape of renal tumors. (1st December 2016)

• Record Type: Journal Article
• Authors: Chinello, Clizia; L'imperio, Vincenzo; Stella, Martina; Smith, Andrew James; Bovo, Giorgio; Grasso, Angelica; Grasso, Marco; Raimondo, Francesca; Pitto, Marina; Pagni, Fabio; Magni, Fulvio
• Is Part Of: Expert review of proteomics. Volume 13:Number 12(2016)
• Page Start: 1103
• Page End: 1120
• Publication Date: 2016-12-01
• Subjects: Renal cell carcinoma -- tissue -- biological fluids -- biomarkers -- proteomics -- mass spectrometry imaging -- peptidome -- proteome -- kidney -- cancer; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1080/14789450.2016.1248415
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Introduction : Renal cell carcinoma (RCC) is the most fatal of the common urologic cancers, with approximately 35% of patients dying within 5 years following diagnosis. Therefore, there is a need for non-invasive markers that are capable of detecting and determining the severity of small renal masses at an early stage in order to tailor treatment and follow-up. Proteomic studies have proved to be very useful in the study of tumors. Areas covered : In this review, we will detail the current knowledge obtained by the different proteomic approaches, focusing on MS-based strategies, used to investigate RCC biology in order to identify diagnostic, prognostic and predictive biomarkers on tissue, cultured cells and biological fluids. Expert commentary : Currently, no reliable biomarkers or targets for RCC have been translated into the clinical setting. Moreover, despite the efforts of proteomics and other -omics disciplines, only a small number of them have been observed as shared targets between the different analytical platforms and biological specimens. The difficulty to define a specific molecular pattern for RCC and its subtypes highlights a peculiar profile and a heterogeneity that must be taken into account in future studies.